Ramucirumab
Vegf/Vegfr (Vascular Endothelial Growth Factor / -Receptor) Inhibitors
Sold as Cyramza
- Drug class
- Vegf/Vegfr (Vascular Endothelial Growth Factor / -Receptor) Inhibitors
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 7
Overview
Ramucirumab is an active pharmaceutical ingredient in the Vegf/Vegfr (Vascular Endothelial Growth Factor / -Receptor) Inhibitors group (L01FG). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 5 | April 10, 2026 |
| EU European Union | EMA | 1 | January 16, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
5 products
Uses
1). 1). Colorectal cancer Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.
1). Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy. Hepatocellular carcinoma Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.
EUEuropean Union· EMA
1 product
Uses
1). 1). Colorectal cancer Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.
1). Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy. Hepatocellular carcinoma Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.
CACanada· Health Canada
1 product
Uses
CYRAMZA® (ramucirumab) is indicated for: • Gastric Cancer – CYRAMZA (ramucirumab) as a single agent or in combination with paclitaxel is indicated for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma, with disease progression on or after prior platinum and fluoropyrimidine chemotherapy.
1 Pediatrics Pediatrics (< 18 years of age) The safety and effectiveness of CYRAMZA in children and adolescents have not been established. Therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatrics (≥ 65 years of age) No overall differences in safety or effectiveness have been observed between the elderly and younger patients, but greater safety sensitivity of some older individuals cannot be ruled out.
Drug interactions
Known interactions involving Ramucirumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB148950241 · revised April 10, 2026
- [2]European Medicines Agency · EMEA/H/C/002829 · revised January 16, 2026
- [3]Health Canada (DPD) · 02443805 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.